<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388738</url>
  </required_header>
  <id_info>
    <org_study_id>CIB-NBS-C</org_study_id>
    <nct_id>NCT01388738</nct_id>
  </id_info>
  <brief_title>Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.</brief_title>
  <acronym>3C</acronym>
  <official_title>Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Institute of the Brain, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Veropharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Institute of the Brain, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's
      very important to choose the right way of the management of the patient and an appropriate
      drugs.

      There is a large number of the so-called neuroprotective drugs, which were effective in
      laboratory, but didn't show positive results in clinical studies with using traditional
      clinical scales scores as a primary outcome measures.

      Specialists suggest, that the investigators could receive better results if the investigators
      change design of the studies, particularly if the investigators select more precise and
      sensitive method of assessment.

      Aim of this study: to determine the role of navigated brain stimulation (NBS) for evaluation
      of the changes in the motor centers and motor tracts after administration of different
      cerebroprotective drugs. (The substances won't be compared to each other).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MEP(motor evoked potential) parameter: motor threshold</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MEP(motor evoked potential) parameter: latency</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MEP(motor evoked potential) parameter: amplitude</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) Scale for Muscle Strength scores</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel index</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Alpha waves percentage</measure>
    <time_frame>2 months</time_frame>
    <description>EEG parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beta waves percentage</measure>
    <time_frame>2 months</time_frame>
    <description>EEG parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Delta waves percentage</measure>
    <time_frame>2 months</time_frame>
    <description>EEG parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Theta waves percentage</measure>
    <time_frame>2 months</time_frame>
    <description>EEG parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of the abnormal epileptiform activity</measure>
    <time_frame>2 months</time_frame>
    <description>EEG parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>cerebrolysin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Alpha glycerylphosphorylcholine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>citicoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV and per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citicoline</intervention_name>
    <description>citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os</description>
    <arm_group_label>citicoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Alpha glycerylphosphorylcholine</intervention_name>
    <description>choline alfoscerate IV 1000mg daily 10 days</description>
    <arm_group_label>L-Alpha glycerylphosphorylcholine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cerebrolysin</intervention_name>
    <description>Cerebrolysin IV 10 ml daily 10 days</description>
    <arm_group_label>cerebrolysin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients from 3 to 6 months after ischemic stroke

          -  hemispheric infarction

          -  paresis from 2 to 4 scores by Medical Research Council Weakness Scale (MRC)

        Exclusion Criteria:

          -  history of seizures

          -  pregnancy, lactation

          -  cognitive deficiency (poor compliance)

          -  acute renal failure

          -  acute hepatic failure

          -  oncological history

          -  cardiac pacemakers and other metal implants

          -  regular intake of any nootropic drugs

          -  Modified Ashford Scale scores 3 and more

          -  regular intake of anticonvulsants, neuromuscular relaxants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Institute of Brain</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk region</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2011</study_first_posted>
  <last_update_submitted>December 22, 2011</last_update_submitted>
  <last_update_submitted_qc>December 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>prof. Andrey A. Belkin, MD, PhD</name_title>
    <organization>Clinical Institute of the Brain, Russia</organization>
  </responsible_party>
  <keyword>Navigation Brain Stimulation (NEXSTIM)</keyword>
  <keyword>cerebroprotective drug effectiveness</keyword>
  <keyword>acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

